Examining the Role of Type 2 Inflammation in Eosinophilic Esophagitis-Reference-Cited by-同舟云学术

Examining the Role of Type 2 Inflammation in Eosinophilic Esophagitis

Published:2022 Issue:5 Volume:1 Page:720-732
ISSN:2772-5723
Container-title:Gastro Hep Advances
language:en
Short-container-title:Gastro Hep Advances

Author:

Chehade Mirna,Falk Gary W.,Aceves Seema,Lee Jason K.,Mehta Vinay,Leung John,Shumel Brad,Jacob-Nara Juby A.,Deniz Yamo,Rowe Paul J.,Cunoosamy Danen,Khodzhayev Angela

Funder

Sanofi US

Regeneron Pharmaceuticals Inc

Publisher

Elsevier BV

Reference136 articles.

1. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference;Dellon;Gastroenterology,2018

2. Emerging therapies for eosinophilic esophagitis;Greuter;J Allergy Clin Immunol,2020

3. Diagnosis and treatment of eosinophilic esophagitis;Gonsalves;J Allergy Clin Immunol,2020

4. Mechanisms of disease of eosinophilic esophagitis;Davis;Annu Rev Pathol,2016

5. Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-β1, and increase esophageal smooth muscle contraction;Aceves;J Allergy Clin Immunol,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial;The Lancet Gastroenterology & Hepatology;2023-11

2. Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy;Pharmaceutics;2023-09-21

3. Therapeutical Targets in Allergic Inflammation;Biomedicines;2022-11-09